The project, carried out at Stanford University, has reached the stage of animal trials, and the next step will be conducting clinical trials involving humans.
Researchers are using an innovative approach that significantly differs from the methods employed in traditional vaccines for over two centuries.
Although the research is still in its early stages, medical experts note promising results and express hope that this vaccine will become an important milestone in the fight against lung diseases.
